TY - JOUR
T1 - Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD
T2 - An exploratory study
AU - Faraone, Stephen V.
AU - Spencer, Thomas J.
AU - Kollins, Scott H.
AU - Glatt, Stephen J.
AU - Goodman, David
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research and/or authorship of this article: In the past year, Dr. Faraone received consulting fees and was on Advisory Boards for Shire Development and received research support from Shire and the National Institutes of Health (NIH). In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by Shire, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. In previous years, he received research support from Eli Lilly, Shire, Pfizer and the NIH. Dr. Faraone receives royalties from a book published by Guilford Press: Straight Talk About Your Child’s Mental Health. Dr. Stephen Glatt is currently receiving research support from the National Institutes of Health. In previous years, Dr. Glatt has received research support, consulting fees or has been a speaker for the following sources: Shire Laboratories, and the National Institutes of Health. Dr. Thomas Spencer receives research support from the following sources: Shire Laboratories Inc, Cephalon, Eli Lilly & Company, Glaxo-Smith Kline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, Pfizer, and NIMH. Dr. Thomas Spencer is a speaker for the following speaker’s bureaus: Shire Laboratories, Inc, Eli Lilly & Company, Glaxo-Smith Kline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals. Dr. Thomas Spencer has been on advisory boards for the following pharmaceutical companies: Shire Laboratories Inc, Cephalon, Eli Lilly & Company, Glaxo-Smith Kline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, and Pfizer. Dr. Kollins has received research support from the following sources in the past 24 months: Addrenex Pharmaceuticals, Comentis, Inc., Shire Pharmaceuticals, NIDA, NIMH, NINDS, NIEHS, & EPA. Dr. Kollins has received consulting fees from the following sources in the past 24 months: Addrenex Pharmaceuticals, Comentis, Inc., Shire Pharmaceuticals, and NIDA. Dr. Goodman has received research support from Shire Laboratories Inc, Cephalon, Eli Lilly & Company, McNeil Pharmaceutical, New River Pharmaceuticals. Dr. Goodman is a speaker for Shire Laboratories, Inc, McNeil Pharmaceutical, Wyeth and Forest. Dr. Goodman has been on advisory boards and/or consultant to Shire Laboratories Inc, McNeil Pharmaceutical, Clinical Global Advisors, Thompson Reuters.
Funding Information:
Stephen J. Glatt, PhD, is an assistant professor of psychiatry and behavioral sciences and of neuroscience and physiology, associate director of the Medical Genetics Research Center, and director of the Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab) at SUNY Upstate Medical University. He has received research support from the U.S. National Institutes of Health, NARSAD: The Brain and Behavior Research Fund, and the Sidney R. Baer, Jr. Foundation. He is working primarily on candidate gene and genome-wide association and expression studies of schizophrenia, bipolar disorder, autism, ADHD, heroin dependence, and other substance use disorders.
PY - 2012/2
Y1 - 2012/2
N2 - Objective: To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD. Method: This was a 4-week, randomized, double-blinded, placebo-controlled, parallel-group, forced-dose titration study in adult participants, aged 18 to 55 years, meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) criteria for ADHD. Results: Nearly all participants assigned to an LDX dose achieved their assigned dose with the exception of about 4% of participants assigned to the 50 mg or 14% assigned to the 70 mg doses. Higher doses of LDX led to greater improvements in ADHD-rating scale scores, independent of prior pharmacotherapy. This was evident for both inattentive and hyperactive-impulsive symptoms. The authors found some evidence for an interaction between LDX dose and baseline severity of ADHD symptoms. Conclusion: For LDX doses between 30 and 70 mg/d, the dose-response efficacy effect for LDX is not affected by prior pharmacotherapy, but patients with a greater severity of illness may benefit more from higher doses, especially for hyperactive-impulsive symptoms. The results do not provide information about doses above 70 mg/d, which is the maximum approved dose of LDX and the highest dose studied in ADHD clinical trials.
AB - Objective: To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD. Method: This was a 4-week, randomized, double-blinded, placebo-controlled, parallel-group, forced-dose titration study in adult participants, aged 18 to 55 years, meeting Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.) criteria for ADHD. Results: Nearly all participants assigned to an LDX dose achieved their assigned dose with the exception of about 4% of participants assigned to the 50 mg or 14% assigned to the 70 mg doses. Higher doses of LDX led to greater improvements in ADHD-rating scale scores, independent of prior pharmacotherapy. This was evident for both inattentive and hyperactive-impulsive symptoms. The authors found some evidence for an interaction between LDX dose and baseline severity of ADHD symptoms. Conclusion: For LDX doses between 30 and 70 mg/d, the dose-response efficacy effect for LDX is not affected by prior pharmacotherapy, but patients with a greater severity of illness may benefit more from higher doses, especially for hyperactive-impulsive symptoms. The results do not provide information about doses above 70 mg/d, which is the maximum approved dose of LDX and the highest dose studied in ADHD clinical trials.
KW - ADHD
KW - amphetamine
KW - dose-response
KW - lisdexamfetamine dimesylate
KW - stimulants
UR - http://www.scopus.com/inward/record.url?scp=84856014498&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856014498&partnerID=8YFLogxK
U2 - 10.1177/1087054711403716
DO - 10.1177/1087054711403716
M3 - Article
C2 - 21527575
AN - SCOPUS:84856014498
VL - 16
SP - 118
EP - 127
JO - Journal of Attention Disorders
JF - Journal of Attention Disorders
SN - 1087-0547
IS - 2
ER -